Obesity in the UAE: 2026 Statistics & The GLP-1 Research Landscape
Prevalence data from the largest Middle Eastern cross-sectional study (440,000+ adults), demographic breakdowns, diabetes comorbidity rates, and the rapidly expanding GLP-1 receptor agonist market in the United Arab Emirates.
Update History ▾
Initial publication
The UAE has one of the highest obesity rates globally. A 2025 cross-sectional study of over 440,000 adults in Dubai found that 63% are overweight or obese and 28% are obese (BMI ≥30). UAE nationals show higher rates (68.3%) than expatriate populations. Diabetes prevalence stands at 19.3% — among the world’s highest. The UAE GLP-1 receptor agonist market is the fastest growing in the Middle East & Africa, projected to reach USD 371.6 million by 2030.
Janoshik-verified, HPLC ≥99.2% purity. Retatrutide Pen 30 mg from AED 1,000/pen. Ships from Dubai.
| Metric | Value | Source / Year |
|---|---|---|
| Adult overweight + obesity (Dubai) | 63% | Abdelgadir et al. 2025 (n=440,000+) |
| Adult obesity (BMI ≥30) | 28.0% | Abdelgadir et al. 2025 |
| UAE nationals overweight/obese | 68.3% | Abdelgadir et al. 2025 |
| Diabetes prevalence (adults) | 19.3% | IDF Diabetes Atlas / WHO |
| Study population | 440,000+ adults in Dubai | Cross-sectional study |
| GLP-1 market size (UAE, projected 2030) | USD 371.6 million | Grand View Research |
| GLP-1 market growth rate (UAE) | Fastest in MENA region | Grand View Research |
| Semaglutide UAE launch | Late 2020 | Novo Nordisk |
| Tirzepatide UAE launch | Mid-2022 | Eli Lilly |
| Monthly cost of Ozempic (AED) | 744–1,200 | UAE pharmacy data |
| Monthly cost of Mounjaro (AED) | ~1,734 | UAE pharmacy data |
How Severe Is the Obesity Problem in the UAE?
The United Arab Emirates ranks among the top 20 countries globally for adult obesity prevalence, a position driven by decades of rapid urbanization, increasingly sedentary lifestyles, and a population-wide shift toward calorie-dense processed diets. The metabolic burden is not a marginal concern—it is a defining public health challenge for the nation. For a detailed look at pricing and access, see our GLP-1 medications UAE availability guide.
The 2025 cross-sectional study by Abdelgadir et al., published in Diabetes, Obesity and Metabolism, is the largest of its kind in the Middle East, encompassing over 440,000 adults in Dubai. The findings are stark: 63% of the adult population meets the criteria for overweight or obesity, and 28% fall into the obese category (BMI ≥30). These figures exceed global averages and position Dubai as a critical epicenter for metabolic disease research.
Men and women show comparable overall rates, though the patterns diverge by age group—obesity prevalence increases sharply in women after age 40, while men show earlier onset in their 30s. Notably, UAE nationals (Emiratis) demonstrate significantly higher rates at 68.3% overweight or obese, compared to the broader expatriate population. This disparity points to complex interactions between genetic predisposition, cultural dietary patterns, and lifestyle factors unique to the national population. For a broader ranking of research compounds addressing metabolic disease, see our best research peptides 2026 guide.
What Are the Diabetes and Metabolic Comorbidities?
With a diabetes prevalence of 19.3% among adults, the UAE ranks among the highest in the world—a figure that has risen steadily over the past two decades. The correlation between the nation’s obesity rates and type 2 diabetes (T2D) prevalence is well-documented: the metabolic dysfunction associated with excess adiposity directly drives insulin resistance, beta-cell exhaustion, and eventual glycemic failure.
The comorbidity profile extends beyond diabetes. Rising rates of thyroid disorders in the Emirati population create additional clinical considerations for GLP-1 receptor agonist use, as these compounds carry precautionary labeling regarding medullary thyroid carcinoma risk from preclinical rodent studies. Researchers investigating GLP-1 mechanisms in UAE populations must account for this elevated baseline thyroid pathology.
Cardiovascular disease remains the leading cause of death in the UAE, and the metabolic syndrome triad of obesity, diabetes, and dyslipidemia is the primary modifiable risk factor. This convergence of metabolic conditions creates an urgent clinical need for effective interventions—and a compelling research environment for studying the multi-pathway mechanisms of next-generation metabolic compounds. Researchers exploring alternatives to branded semaglutide may find our Ozempic alternatives in Dubai overview useful.
- Retatrutide (triple agonist) — research only
- CagriSema (amylin + GLP-1) — Phase 3 trials
- Mazdutide (dual agonist) — approved in China
- Oral GLP-1 formulations in development
- Market projected USD 371.6M by 2030
- Fastest growing GLP-1 market in MENA region
Why Is Dubai a Key Market for Metabolic Research?
The convergence of high obesity prevalence and a wealthy, health-conscious population creates an environment of urgent clinical need paired with economic capacity. Unlike many markets where cost barriers limit access to GLP-1 therapies, a significant segment of the UAE population is willing and able to pay out-of-pocket for metabolic treatments—particularly given gaps in insurance coverage for weight management medications.
Dubai’s strategic geographic position at the crossroads of Asia, Africa, and Europe makes it an increasingly attractive hub for clinical trials and metabolic research. The city’s free zone regulatory framework supports the distribution of research compounds under clear legal parameters, and a growing number of metabolic research clinics and academic institutions provide the infrastructure necessary for rigorous investigation. Our obesity drug approval tracker 2026 covers the full regulatory pipeline relevant to this market.
The combination of a genetically diverse population (Emirati nationals alongside expatriates from over 200 countries), high disease burden, and regulatory openness to research innovation positions the UAE as one of the most compelling markets globally for next-generation GLP-1 receptor agonist research—from single-agonist compounds through to triple-agonist investigational peptides like Retatrutide. For a head-to-head data comparison of these next-generation compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Abdelgadir E, et al. Prevalence of overweight and obesity in adults from the Middle East. Diabetes Obes Metab. 2025. (No DOI available — recent publication)
- Grand View Research. UAE GLP-1 Receptor Agonist Market Outlook 2030.
- World Obesity Federation. UAE Country Profile. data.worldobesity.org
- IDF Diabetes Atlas, 10th Edition. International Diabetes Federation. diabetesatlas.org
- Semaglutide and weight management in the Arab countries. ScienceDirect. 2025. ScienceDirect Search
- Dubai Health Authority. Health Statistics Annual Report. dha.gov.ae
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.
Order Retatrutide Pen →